News - Royalty Pharma

Filter

Current filters:

Royalty Pharma

Popular Filters

Royalty Pharma sells on portion of ibrutinib royalties

12-08-2013

US private equity firm Royalty Pharma says it has sold to Aisling Capital and Clarus Ventures around…

ibrutinibLicensingOncologyPharmaceuticalRoyalty Pharma

Quest Diagnostics sells ibrutinib royalty rights for $485 million

19-07-2013

USA-based diagnostic services firm Quest Diagnostics (NYSE: DGX) says it has completed the sale of its…

FinancialibrutinibLicensingOncologyPharmaceuticalQuest DiagnosticsRoyalty Pharma

Royalty pulls plug on Elan buy (for now?); analysts' view on what comes next

19-06-2013

In the ongoing hostile takeover saga, US private equity firm Royalty Pharma has withdrawn its request…

ElanMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Royalty Pharma hostile bid lapses as Elan shareholders vote for share repurchase but not Theravance, AOP or ELND005 deals

17-06-2013

At the company's Extraordinary General Meeting held earlier today (June 17), shareholders of Ireland-based…

ElanMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Elan puts up formal "for sale" notice

17-06-2013

Ireland-based Elan Corp (NYSE:ELN), which has been the subject of a hostile takeover campaign by private…

Biogen IdecElanMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Royalty bid for Elan could be withdrawn; J&J sells 25.4 million Elan shares

14-06-2013

Ireland-based hostile takeover target Elan (NYSE: ELN) fell 5.2% to 9.29 euros on June 13, the most in…

ElanJohnson & JohnsonMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Elan board unreservedly rejects Royalty's increased tender offer

11-06-2013

Ireland-based drugmaker Elan Corp (NYSE: ELN) says that its board of directors, after careful review…

ElanMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Royalty Pharma hikes offer for Elan to $13 a share, plus CVR of up to $2.50

10-06-2013

Ireland-based Elan Corp (NYSE: ELN) saw its shares to 5.3% to $13.35 by mid morning last Friday (June…

ElanMergers & AcquisitionsPharmaceuticalRoyalty PharmaTysabri

Elan details further inadequacy of Royalty Pharma's revised offer; takes legal action

04-06-2013

The saga of Royalty Pharma's hostile attempts to acquire Ireland-headquartered Elan Corp (NYSE: ELN)…

ElanLegalMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Elan tells shareholders it is worth up to $20.80 a share and they should not accept Royalty's $12.50 offer

30-05-2013

In the ongoing saga of Royalty Pharma's takeover attempts, Ireland-based Elan (NYSE: ELN) has communicated…

ElanFinancialMergers & AcquisitionsPharmaceuticalRoyalty PharmaTysabri

Elan rejects Royalty Pharma's increased bid; prices Senior Notes offering

24-05-2013

Ireland-based takeover target Elan Corp (NYSE: ELN) says that its board of directors, after careful review…

ElanFinancialMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Royalty Pharma ups bid for Elan to $12.50 a share

21-05-2013

ot on the heels of Ireland-based drugmaker Elan Corp's (NYSE: ELN) own acquisition plans (it is to buy…

ElanMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Briefs: Royalty sweetens offer for Elan; AstraZeneca biomarker deal

16-04-2013

US private equity company Royalty Pharma today (April 15) issued a firm improved takeover offer for Ireland-based…

AstraZenecaElanLicensingMergers & AcquisitionsOncologyOxford Cancer BiomarkersPharmaceuticalResearchRoyalty Pharma

Elan to unlock benefits for shareholders from Tysabri deal

05-03-2013

The board of Ireland-based drugmaker Elan Corp (NYSE:ELN) has approved the decision to initiate a unique…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsPharmaceuticalRoyalty PharmaTysabri

Elan calls Royalty Pharma approach "highly opportunistic"

26-02-2013

The board of Ireland-based drugmaker Elan Corp (NYSE: ELN) has acknowledged the takeover approach from…

ElanFinancialMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Royalty Pharma makes unsolicited bid for Elan

25-02-2013

Royalty Pharma said this morning that contact was made on Monday February 18, 2013 with the chairman…

ElanMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Back to top